Lenalidomide with or without Epoetin Alfa in Treating Patients with Myelodysplastic Syndrome and Anemia

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IIITreatment18 and overE2905
NCI-2009-01173, CDR0000634119, ECOG-E2905, NCT00843882

Trial Description

Summary

This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.

Further Study Information

PRIMARY OBJECTIVES:

I. To compare the rate of major erythroid response (MER) between lenalidomide monotherapy and combined treatment of lenalidomide and epoetin alfa in erythropoietin non-responsive low-/intermediate-1 (Int-1)-risk myelodysplastic syndrome (MDS) patients or erythropoietin treatment naïve patients with low probability of erythropoietin benefit.

SECONDARY OBJECTIVES:

I. To compare the time to MER by treatment assignment.

II. To evaluate the duration of MER by treatment assignment.

III. To estimate the frequency of MER to salvage combination therapy in patients who fail to experience a MER with lenalidomide monotherapy.

IV. To evaluate and compare the frequency of minor erythroid response by treatment assignment.

V. To investigate the mechanism and target of lenalidomide action in patients with chromosome 5q31.1 deletion.

VI. To evaluate the frequency of cytogenetic response and progression, and the relationship between cytogenetic pattern and erythroid response.

VII. To evaluate the frequency of bone marrow response (complete response [CR] + partial response [PR]).

VIII. To evaluate the relationship between erythroid response and laboratory correlates outlined below: pretreatment and on study endogenous erythropoietin level (Arm A); to evaluate the effect of cluster of differentiation (CD)45 isoform profile on lenalidomide enhancement of erythropoietin-induced signal transducer and activator of transcription 5A (STAT5) phosphorylation in CD71^Hi erythroid precursors and the relationship to erythroid response; to characterize molecular targets relevant to lenalidomide cytotoxicity in del5q31.1 cells; to evaluate the frequency of cryptic chromosome 5q31.1 deletions in patients with non-del5q31.1 MDS by array-based genomic scan, and to determine the relationship to hematologic response.

OUTLINE: Patients are randomized to 1 of 2 treatment arms. Patients with del 5q31.1 karyotype are assigned to Arm A.

ARM A: Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21.

ARM B: Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa subcutaneously (SC) once weekly.

In both arms, treatment repeats every 28 days for 4 courses. Patients who achieve a major erythroid response (MER) may continue treatment beyond 4 courses in the absence of disease progression, disease conversion to acute myeloid leukemia, or unacceptable toxicity. Patients in Arm A who fail to achieve MER or who achieve MER but relapse after 16 weeks of treatment with lenalidomide may crossover and receive treatment in Arm B.

After completion of study treatment, patients are followed up for 6 months.

Eligibility Criteria

Inclusion Criteria:

Patient must have IPSS categories of low- or intermediate-1-risk disease; patients must have IPSS score determined by cytogenetic analysis prior to randomization; patients must have cytogenetic analysis done (to calculate IPSS); if the current bone marrow biopsy is a dry tap, patients with cytogenetic failure and < 10% marrow blasts will be eligible; subjects with cytogenetic failure must have previous cytogenetic results (fluorescence in situ hybridization [FISH] is not a substitute) within the last 6 months post last type of MDS treatment (in this case, not referring to growth factors as type of MDS treatment)

NOTE: Results of the bone marrow biopsy and aspirate as well as cytogenetics are mandatory to register subjects onto study, which are indispensable to determine International Prognostic Scoring System (IPSS) category needed for eligibility; please note that it is not necessary to wait for the week 16, week 32, or week bone marrow and cytogenetic results prior to starting the next cycle unless deemed necessary by the treating physician; one example of this exception can include if the subject shows signs of progression, such as increased peripheral blood blast percentage; at that juncture, the treating physician may prefer to await the results prior to starting a new cycle; if a cycle is started, and based on the bone marrow results it is felt by the treating physician that the subject should not continue on treatment, please be sure to note this information on the case report forms at end of treatment

Patients must not have clinically significant anemia resulting from iron, B12 or folate deficiencies, autoimmune or hereditary hemolysis, or gastrointestinal bleeding

Patients must not have prior history of desquamating rash from thalidomide at time of study entry

Prior thalidomide is allowed, however, patients must not have prior >= grade-3 allergic reactions to thalidomide

Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamate pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) =< 2.0 x ULN

Serum creatinine =< 1.5 times upper limit of normal (ULN)

Absolute neutrophil count (ANC) >= 500 cells/mcL (0.5 x 10^9/L); hence ANC must be >= 500/mcL without myeloid growth factor support

Platelet count >= 50,000/mcL (50 x 10^9/L) without platelet transfusion

Patients must not have MDS secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseases

Patients must not have proliferative (WBC >= 12,000/mcL) chronic myelomonocytic leukemia (CMML); WBC must be < 12,000/mcL

Patients must not have a diagnosis of uncontrolled seizure or uncontrolled hypertension

Patients must not have prior therapy with lenalidomide

Effective contraception must be used by patients participating in lenalidomide therapy, and all patients must agree to counseling by a trained counselor every 28 days about pregnancy precautions and risks of fetal exposure; females of childbearing potential (FCBP) must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide, during lenalidomide therapy, during dose interruptions, and for at least 28 days following discontinuation of lenalidomide therapy; females of childbearing potential should be referred to a qualified provider of contraceptive methods, if needed; males receiving lenalidomide must agree to use a latex condom during any sexual contact with females of childbearing potential even if they have undergone a successful vasectomy

Women must not be pregnant or breastfeeding; females of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10–14 days and again within 24 hours prior to starting cycle 1 of lenalidomide; a female of childbearing potential (FCBP) is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months; FCBP must also agree to ongoing pregnancy testing)

Patients must not have documented iron deficiency; all patients must have documented marrow iron stores; if marrow iron stain is not available, the transferrin saturation must be > 20% or a serum ferritin > 100 ng/mL

Patients must have a serum erythropoietin level documented before randomization and =< 56 days before day 1 of study treatment; NOTE: hemoglobin must be < 9.5 g/dL at time that serum erythropoietin is drawn

Patients must be off all non-transfusion therapy for MDS for 28 days prior to initiation of study treatment, including all types of growth factors; patients may receive hydrocortisone prophylactically to prevent transfusion reactions

Applies only for patients without the deletion 5q 31.1; patients must have failed treatment with an erythropoietic growth factor, or have a low probability of response to rhu-erythropoietin; patients with low probability of response to rhu-erythropoietin or prior erythropoietin failures are defined as follows:

Prior erythropoietin failure-requires a minimum trial of >= 40,000 units epoetin alfa/week x 8 weeks or equivalent dose of darbepoetin alfa for 8 weeks with failure to achieve transfusion independence in dependent patients or a failure to achieve a >= 2 g rise in hemoglobin sustained for >= 4 weeks in non-transfusion dependent patients

Low erythropoietin response profile-rhu-erythropoietin and epoetin alfa-naïve patients receiving >= 2U packed (p)RBC/month for a minimum of 8 weeks, and serum erythropoietin > 500 mU/mL in the 8 weeks prior to randomization for a hemoglobin < 9.5 g/dL

Must have symptomatic anemia untransfused with hemoglobin < 9.5 g/dL =< 8 weeks prior to randomization or with red blood cells (RBC) transfusion dependence (i.e., >= 2 units/month) confirmed for =< 8 weeks before randomization

NOTE: For non-transfusion dependent patients (i.e., receiving < 2 units/4 weeks x 8 weeks pre-study) who receive periodic transfusions, the mean 8 week pre-transfusion hemoglobin should be used to determine protocol eligibility and response reference

For non-transfusion dependent patients, a minimum of 2 pre-transfusion or un-transfused hemoglobin values are required

Patient must have documented diagnosis of MDS lasting at least three months (MDS duration >= 3 months) according to World Health Organization (WHO) criteria or non-proliferative chronic myelomonocytic leukemia (CMML) (white blood cell [WBC] < 12,000/mcL)

Patients must not have a limiting unresolved grade 3 or greater toxicity from lenalidomide monotherapy or drug intolerance preventing continuation of lenalidomide treatment

Patients must show failure to achieve MER (major erythroid response) or have achieved MER but relapsed on Arm A

Patients must have completed 16 weeks of monotherapy with lenalidomide

Eligibility for crossover registration from Arm A (lenalidomide alone) to Arm B (lenalidomide and epoetin alfa):

Patients must not have a known allergic reaction to epoetin alfa (Procrit) or human serum albumin

Patients must not have known human immunodeficiency virus (HIV)-1 seropositivity

Patients must not have a history of thrombo-embolic events within 3 years prior to study randomization

Patients must not have any serious medical condition or any other unstable medical co-morbidity, or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he/she participates in the study

Patients must not have prior history of malignancy other than MDS (except basal cell or squamous skin cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been confirmed free of disease for >= 3 years

Patients must not have used cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 8 weeks of randomization

Serum total bilirubin < 3.0 mg/dL

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

National Cancer Institute

  • National Cancer Institute
Alan F. List, Principal Investigator

Trial Sites

U.S.A.

Alabama
Birmingham

University of Alabama at Birmingham Cancer Center

Uma Madhav Borate
Ph: 205-934-0309

Uma Madhav Borate
Principal Investigator

Arizona
Scottsdale

Mayo Clinic in Arizona

Mark R. Litzow
Ph: 507-538-7623

Mark R. Litzow
Principal Investigator

California
Baldwin Park

Kaiser Permanente Medical Group - Baldwin Park

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Greenbrae

Marin Cancer Care Inc

Peter David Eisenberg
Ph: 415-925-5000
Email: info@marinspecialtycare.com

Peter David Eisenberg
Principal Investigator

Irvine

Southern California Permanente Medical Group

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Los Angeles

Kaiser Permanente Los Angeles Medical Center

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Panorama City

Kaiser Permanente - Panorama City

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Sacramento

University of California Davis Comprehensive Cancer Center

Jeanna L. Welborn
Ph: 916-734-3089

Jeanna L. Welborn
Principal Investigator

Saint Helena

Saint Helena Hospital

Gregory B. Smith
Ph: 707-967-3698

Gregory B. Smith
Principal Investigator

San Diego

Kaiser Permanente at San Diego

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Kaiser Permanente-San Diego Mission

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

San Marcos

Kaiser Permanente Health Care

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Woodland Hills

Kaiser Permanente

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Colorado
Aurora

The Medical Center of Aurora

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Boulder

Boulder Community Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Colorado Springs

Penrose-Saint Francis Healthcare

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Penrose

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Denver

Colorado Blood Cancer Institute

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Colorado Cancer Research Program CCOP

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Exempla Saint Joseph Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Presbyterian - Saint Lukes Medical Center - Health One

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Midtown

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Rose

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rose Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Durango

Mercy Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Englewood

Comprehensive Cancer Care and Research Institute of Colorado LLC

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Swedish Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Fort Collins

Poudre Valley Hospital

Regina Jeanise Brown
Ph: 970-297-6150

Regina Jeanise Brown
Principal Investigator

Golden

Mountain Blue Cancer Care Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Greeley

North Colorado Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Greenwood Village

Rocky Mountain Cancer Centers-Greenwood Village

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Lakewood

Rocky Mountain Cancer Centers-Lakewood

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Saint Anthony Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Littleton

Littleton Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Lone Tree

Rocky Mountain Cancer Centers-Sky Ridge

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Sky Ridge Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Longmont

Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Loveland

McKee Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Parker

Parker Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Parker

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Pueblo

Saint Mary Corwin Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Wheat Ridge

Exempla Lutheran Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Connecticut
Hartford

Saint Francis Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

New Britain

The Hospital of Central Connecticut

Brian J. Byrne
Ph: 860-224-5660

Brian J. Byrne
Principal Investigator

New Haven

Yale University

Steven D. Gore
Ph: 203-785-5702

Steven D. Gore
Principal Investigator

Delaware
Lewes

Beebe Medical Center

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Newark

Christiana Care Health System-Christiana Hospital

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Delaware Clinical and Laboratory Physicians PA

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Helen F Graham Cancer Center

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Medical Oncology Hematology Consultants PA

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Regional Hematology and Oncology PA

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Rehoboth Beach

Beebe Health Campus

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Seaford

Nanticoke Memorial Hospital

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Florida
Hollywood

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Daren D. Grosman
Ph: 888-823-5923
Email: ctsucontact@westat.com

Daren D. Grosman
Principal Investigator

Jacksonville

Mayo Clinic in Florida

Mark R. Litzow
Ph: 507-538-7623

Mark R. Litzow
Principal Investigator

Leesburg

Leesburg Regional Medical Center

Pablo Centeno Reyes
Email: info@cfhalliance.org

Pablo Centeno Reyes
Principal Investigator

Miami Beach

Mount Sinai Medical Center

Michael A. Schwartz
Ph: 305-674-2625
Email: info@msccop.com

Michael A. Schwartz
Principal Investigator

Tampa

Moffitt Cancer Center

Alan F. List
Ph: 800-456-7121
Email: canceranswers@moffitt.org

Alan F. List
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Saint Luke's Mountain States Tumor Institute

Paul G. Montgomery
Ph: 800-845-4624

Paul G. Montgomery
Principal Investigator

Fruitland

Saint Luke's Mountain States Tumor Institute - Fruitland

Paul G. Montgomery
Ph: 800-845-4624

Paul G. Montgomery
Principal Investigator

Meridian

Saint Luke's Mountain States Tumor Institute - Meridian

Paul G. Montgomery
Ph: 800-845-4624

Paul G. Montgomery
Principal Investigator

Nampa

Saint Luke's Mountain States Tumor Institute - Nampa

Paul G. Montgomery
Ph: 800-845-4624

Paul G. Montgomery
Principal Investigator

Post Falls

Kootenai Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Twin Falls

Saint Luke's Mountain States Tumor Institute-Twin Falls

Paul G. Montgomery
Ph: 800-845-4624

Paul G. Montgomery
Principal Investigator

Illinois
Bloomington

Illinois CancerCare-Bloomington

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Canton

Illinois CancerCare-Canton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carthage

Illinois CancerCare-Carthage

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Chicago

Northwestern University

Olga Frankfurt
Ph: 312-695-1301
Email: cancer@northwestern.edu

Olga Frankfurt
Principal Investigator

Presence Resurrection Medical Center

Christopher G. Rose
Ph: 773-792-5116

Christopher G. Rose
Principal Investigator

University of Chicago Comprehensive Cancer Center

Andrew Saul Artz
Ph: 773-834-7424

Andrew Saul Artz
Principal Investigator

Weiss Memorial Hospital

Stuart A. Krauss
Ph: 773-564-5044

Stuart A. Krauss
Principal Investigator

Decatur

Cancer Care Center of Decatur

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Elmhurst

Elmhurst Memorial Hospital

Lucio Di Nunno
Ph: 630-782-7900
Email: Jrohde@emhc.org

Lucio Di Nunno
Principal Investigator

Eureka

Illinois CancerCare-Eureka

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Evanston

NorthShore University HealthSystem-Evanston Hospital

David L. Grinblatt
Ph: 847-570-2109

David L. Grinblatt
Principal Investigator

Glenview

NorthShore University HealthSystem-Glenbrook Hospital

David L. Grinblatt
Ph: 847-570-2109

David L. Grinblatt
Principal Investigator

Highland Park

NorthShore University HealthSystem-Highland Park Hospital

David L. Grinblatt
Ph: 847-570-2109

David L. Grinblatt
Principal Investigator

Joliet

Joliet Oncology-Hematology Associates Limited

Kulumani M. Sivarajan
Ph: 815-730-3098
Email: maureenc@jolietoncology.com

Kulumani M. Sivarajan
Principal Investigator

Kewanee

Illinois CancerCare-Kewanee Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Macomb

Illinois CancerCare-Macomb

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Ottawa

Illinois CancerCare-Ottawa Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin

Illinois CancerCare-Pekin

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peoria

Illinois CancerCare-Peoria

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peru

Illinois CancerCare-Peru

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Princeton

Illinois CancerCare-Princeton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Rockford

SwedishAmerican Regional Cancer Center/ACT

Harvey E. Einhorn
Ph: 779-696-9400
Email: cancercare@swedishamerican.org

Harvey E. Einhorn
Principal Investigator

Springfield

Central Illinois Hematology Oncology Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southern Illinois University School of Medicine

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Indiana
Elkhart

Michiana Hematology Oncology PC-Elkhart

Bilal Ansari
Ph: 574-237-1328

Bilal Ansari
Principal Investigator

Indianapolis

IU Health Central Indiana Cancer Centers-East

Hillary H. Wu
Ph: 317-356-2422

Hillary H. Wu
Principal Investigator

Lafayette

IU Health Arnett Cancer Care

Thomas I. Jones
Ph: 765-838-6871
Email: thimes@iuhealth.org

Thomas I. Jones
Principal Investigator

Mishawaka

Michiana Hematology Oncology PC-Mishawaka

Bilal Ansari
Ph: 574-237-1328

Bilal Ansari
Principal Investigator

Saint Joseph Regional Medical Center-Mishawaka

Bilal Ansari
Ph: 574-237-1328

Bilal Ansari
Principal Investigator

Plymouth

Michiana Hematology Oncology PC-Plymouth

Bilal Ansari
Ph: 574-237-1328

Bilal Ansari
Principal Investigator

South Bend

Memorial Hospital of South Bend

Thomas Joseph Reid
Ph: 800-284-7370

Thomas Joseph Reid
Principal Investigator

Michiana Hematology Oncology PC-South Bend

Bilal Ansari
Ph: 574-237-1328

Bilal Ansari
Principal Investigator

Northern Indiana Cancer Research Consortium CCOP

Bilal Ansari
Ph: 574-237-1328

Bilal Ansari
Principal Investigator

Westville

Michiana Hematology Oncology-PC Westville

Bilal Ansari
Ph: 574-237-1328

Bilal Ansari
Principal Investigator

Iowa
Ames

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Cedar Rapids

Oncology Associates at Mercy Medical Center

Deborah Weil Wilbur
Ph: 319-363-2690

Deborah Weil Wilbur
Principal Investigator

Clive

Medical Oncology and Hematology Associates-West Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Mercy Cancer Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Des Moines

Medical Oncology and Hematology Associates-Laurel

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Mercy Medical Center - Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Mason City

Mercy Medical Center - North Iowa

Arvind Y. Vemula
Ph: 800-433-3883

Arvind Y. Vemula
Principal Investigator

Ottumwa

Ottumwa Regional Health Center

Praveen Vikas
Ph: 641-684-2742

Praveen Vikas
Principal Investigator

Sioux City

Siouxland Regional Cancer Center

Donald B. Wender
Ph: 712-252-0088

Donald B. Wender
Principal Investigator

West Des Moines

Mercy Medical Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Kansas
Lawrence

Lawrence Memorial Hospital

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Wichita

Wesley Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kentucky
Louisville

Jewish Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Jewish Hospital Medical Center Northeast

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Maryland
Baltimore

Johns Hopkins University/Sidney Kimmel Cancer Center

Amy Elizabeth DeZern
Ph: 410-955-8804
Email: jhcccro@jhmi.edu

Amy Elizabeth DeZern
Principal Investigator

Saint Agnes Hospital

Carole Brennan Miller
Ph: 410-368-2910

Carole Brennan Miller
Principal Investigator

Bethesda

Walter Reed National Military Medical Center

Corey Allan Carter
Ph: 800-411-1222

Corey Allan Carter
Principal Investigator

Massachusetts
Burlington

Lahey Hospital and Medical Center

Alan F. List
Ph: 813-745-7101
Email: alan.list@moffitt.org

Alan F. List
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

University of Michigan Comprehensive Cancer Center

Dale Lee Bixby
Ph: 800-865-1125

Dale Lee Bixby
Principal Investigator

Dearborn

Oakwood Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Wayne State University/Karmanos Cancer Institute

Charles A. Schiffer
Ph: 313-576-9363

Charles A. Schiffer
Principal Investigator

Escanaba

Green Bay Oncology - Escanaba

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Flint

Genesys Hurley Cancer Institute

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Iron Mountain

Green Bay Oncology - Iron Mountain

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Jackson

Allegiance Health

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Kalamazoo

West Michigan Cancer Center

Sunil Nagpal
Ph: 269-373-7458

Sunil Nagpal
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Marquette

Marquette General Hospital

Amy M. Weise
Ph: 313-576-9363

Amy M. Weise
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Port Huron

Saint Joseph Mercy Port Huron

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Saginaw

Saint Mary's of Michigan

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Southfield

Providence Hospital

Howard R. Terebelo
Ph: 248-849-5337
Email: jaswinder.grewal@stjohn.org

Howard R. Terebelo
Principal Investigator

St. Joseph

Lakeland Hospital

Bilal Ansari
Ph: 574-237-1328

Bilal Ansari
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Minnesota
Burnsville

Fairview Ridges Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Coon Rapids

Mercy Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Duluth

Essentia Health Cancer Center

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Edina

Fairview-Southdale Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Fridley

Unity Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Hutchinson

Hutchinson Area Health Care

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Maplewood

Minnesota Oncology Hematology PA-Maplewood

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Saint John's Hospital - Healtheast

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Health Partners Inc

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Hennepin County Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Minneapolis Veterans Medical Center

Sharon Davis Luikart
Ph: 612-467-2800

Sharon Davis Luikart
Principal Investigator

Robbinsdale

North Memorial Medical Health Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Rochester

Mayo Clinic

Mark R. Litzow
Ph: 507-538-7623

Mark R. Litzow
Principal Investigator

Saint Cloud

Coborn Cancer Center at Saint Cloud Hospital

Donald James Jurgens
Ph: 877-229-4907
Email: coborncancercenter@centracare.com

Donald James Jurgens
Principal Investigator

Saint Louis Park

Park Nicollet Clinic - Saint Louis Park

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Saint Paul

Regions Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

United Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Shakopee

Saint Francis Regional Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Waconia

Ridgeview Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Willmar

Rice Memorial Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Woodbury

Minnesota Oncology and Hematology PA-Woodbury

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Missouri
Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southeast Cancer Center

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Columbia

University of Missouri - Ellis Fischel

Clint Daniel Kingsley
Ph: 573-882-7440

Clint Daniel Kingsley
Principal Investigator

Jefferson City

Capital Region Medical Center-Goldschmidt Cancer Center

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Kansas City

Saint Luke's Hospital of Kansas City

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Rakesh Gaur
Principal Investigator

Saint Louis

Missouri Baptist Medical Center

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Saint Anthony's Medical Center

Minxiang (Michael) Gu
Ph: 888-823-5923
Email: ctsucontact@westat.com

Minxiang (Michael) Gu
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Bozeman

Bozeman Deaconess Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Butte

Saint James Community Hospital and Cancer Treatment Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Great Falls

Benefis Healthcare- Sletten Cancer Institute

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nebraska
Grand Island

CHI Health Saint Francis

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Kearney

CHI Health Good Samaritan

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Lincoln

Nebraska Cancer Research Center

Gamini S. Soori
Ph: 402-991-8070
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Nevada
Las Vegas

Cancer and Blood Specialists-Fort Apache

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Nevada Cancer Research Foundation CCOP

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

New Hampshire
Keene

Cheshire Medical Center-Dartmouth-Hitchcock Keene

James M. Nickerson
Ph: 603-354-5454ext2155
Email: jmichelson@cheshire-med.com

James M. Nickerson
Principal Investigator

New Jersey
Camden

Cooper Hospital University Medical Center

Neil A. Lachant
Ph: 856-325-6757

Neil A. Lachant
Principal Investigator

East Orange

Veterans Adminstration New Jersey Health Care System

Victor Tsu-Shih Chang
Ph: 800-475-2336
Email: patricia.goyer@med.va.gov

Victor Tsu-Shih Chang
Principal Investigator

Newark

Newark Beth Israel Medical Center

Lori Schleicher
Ph: 973-926-7230

Lori Schleicher
Principal Investigator

Vineland

Inspira Medical Center Vineland

Tami Lee Bach
Ph: 856-641-7933

Tami Lee Bach
Principal Investigator

Woodbury

Inspira Medical Center Woodbury

Tami Lee Bach
Ph: 856-641-7933

Tami Lee Bach
Principal Investigator

New York
Bronx

Albert Einstein College of Medicine

Amit Kumar Verma
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Amit Kumar Verma
Principal Investigator

Montefiore Medical Center - Moses Campus

Amit Kumar Verma
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Amit Kumar Verma
Principal Investigator

Mineola

Winthrop University Hospital

Harry Staszewski
Ph: 866-946-8476

Harry Staszewski
Principal Investigator

Rochester

University of Rochester

Jonathan Willmann Friedberg
Ph: 585-275-5830

Jonathan Willmann Friedberg
Principal Investigator

Syracuse

State University of New York Upstate Medical University

Teresa Caroline Gentile
Ph: 315-464-5476

Teresa Caroline Gentile
Principal Investigator

North Carolina
Clinton

Southeastern Medical Oncology Center-Clinton

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Goldsboro

Southeastern Medical Oncology Center-Goldsboro

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Wayne Memorial Hospital

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Jacksonville

Southeastern Medical Oncology Center-Jacksonville

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Raleigh

Rex Cancer Center

Jeremiah Chad Boles
Ph: 919-784-7209

Jeremiah Chad Boles
Principal Investigator

Rex Cancer Center of Wakefield

Jeremiah Chad Boles
Ph: 919-784-7209

Jeremiah Chad Boles
Principal Investigator

Statesville

Iredell Memorial Hospital

Ruby Ann Grimm
Ph: 704-873-5661

Ruby Ann Grimm
Principal Investigator

Wilson

Southeastern Medical Oncology Center-Wilson

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Winston-Salem

Wake Forest University Health Sciences

Bayard Lowery Powell
Ph: 336-713-6771

Bayard Lowery Powell
Principal Investigator

Ohio
Canton

Aultman Health Foundation

Kisa Ewing Weeman
Ph: 330-363-6891

Kisa Ewing Weeman
Principal Investigator

Mercy Medical Center

Mitchell Haut
Ph: 888-293-4673

Mitchell Haut
Principal Investigator

Cincinnati

Good Samaritan Hospital - Cincinnati

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

TriHealth Cancer Institute-Anderson

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

TriHealth Cancer Institute-Westside

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Lima

Saint Rita's Medical Center

Henry Gerad
Ph: 419-226-9617

Henry Gerad
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

Mohamad Cherry
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Mohamad Cherry
Principal Investigator

Oregon
Coos Bay

Bay Area Hospital

Bret Alan Cook
Ph: 541-269-8392
Email: cherie.cox@bayareahospital.org

Bret Alan Cook
Principal Investigator

Pennsylvania
Abington

Abington Memorial Hospital

Willard G. Andrews
Ph: 215-481-2402

Willard G. Andrews
Principal Investigator

Carlisle

Carlisle Regional Cancer Center

David F. Claxton
Ph: 717-531-3779
Email: CTO@hmc.psu.edu

David F. Claxton
Principal Investigator

Danville

Geisinger Medical Center

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Ephrata

Ephrata Cancer Center

Wilfred A. Layne
Ph: 717-738-4070

Wilfred A. Layne
Principal Investigator

Ephrata Community Hospital

Wilfred A. Layne
Ph: 717-738-4070

Wilfred A. Layne
Principal Investigator

Gettysburg

Adams Cancer Center

Wilfred A. Layne
Ph: 717-738-4070

Wilfred A. Layne
Principal Investigator

Hanover

Cherry Tree Cancer Center

Wilfred A. Layne
Ph: 717-738-4070

Wilfred A. Layne
Principal Investigator

Hazleton

Geisinger Medical Center-Cancer Center Hazleton

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Hershey

Penn State Milton S Hershey Medical Center

David F. Claxton
Ph: 717-531-3779
Email: CTO@hmc.psu.edu

David F. Claxton
Principal Investigator

Philadelphia

University of Pennsylvania/Abramson Cancer Center

Selina M. Luger
Ph: 800-474-9892

Selina M. Luger
Principal Investigator

Phoenixville

Phoenixville Hospital

Carl W. Sharer
Ph: 610-983-1908

Carl W. Sharer
Principal Investigator

Pottstown

Pottstown Memorial Medical Center

Wei (Frank) Song
Ph: 610-327-7544

Wei (Frank) Song
Principal Investigator

Sayre

Guthrie Medical Group PC-Robert Packer Hospital

Bradley Walter Lash
Ph: 800-836-0388

Bradley Walter Lash
Principal Investigator

State College

Mount Nittany Medical Center

David F. Claxton
Ph: 717-531-3779
Email: CTO@hmc.psu.edu

David F. Claxton
Principal Investigator

West Chester

Chester County Hospital

William Emil Luginbuhl
Ph: 610-431-5297

William Emil Luginbuhl
Principal Investigator

West Reading

Reading Hospital

Terrence Paul Cescon
Ph: 610-988-9323

Terrence Paul Cescon
Principal Investigator

Wilkes-Barre

Geisinger Wyoming Valley/Henry Cancer Center

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Williamsport

Susquehanna Cancer Center

Warren Lewis Robinson
Ph: 800-598-4282

Warren Lewis Robinson
Principal Investigator

York

WellSpan Health-York Hospital

Wilfred A. Layne
Ph: 717-738-4070

Wilfred A. Layne
Principal Investigator

South Carolina
Easley

Greenville Health System Cancer Institute-Easley

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Butternut

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Eastside

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Faris

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Memorial Hospital

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Saint Francis Hospital

Robert D. Siegel
Ph: 864-255-1713

Robert D. Siegel
Principal Investigator

Greer

Greenville Health System Cancer Institute-Greer

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Joshua Cole Lukenbill
Ph: 605-716-3982
Email: research@rcrh.org

Joshua Cole Lukenbill
Principal Investigator

Sioux Falls

Avera Cancer Institute

Addison R. Tolentino
Ph: 800-657-4377
Email: Jan.Healy@avera.org

Addison R. Tolentino
Principal Investigator

Tennessee
Knoxville

Thompson Cancer Survival Center

Samuel Spence McCachren
Ph: 865-541-1812

Samuel Spence McCachren
Principal Investigator

Virginia
Danville

Danville Regional Medical Center

Qiwei William Gai
Ph: 434-793-0044

Qiwei William Gai
Principal Investigator

Martinsville

Memorial Hospital Of Martinsville

Sreedhar Katragadda
Ph: 276-666-7827

Sreedhar Katragadda
Principal Investigator

West Virginia
Charleston

West Virginia University Charleston

Steven James Jubelirer
Ph: 304-344-3457

Steven James Jubelirer
Principal Investigator

Morgantown

West Virginia University Healthcare

Michael David Craig
Ph: 304-293-2745
Email: sfilburn@hsc.wvu.edu

Michael David Craig
Principal Investigator

Princeton

Princeton Community Hospital

Rowena Gonzales-Chambers
Ph: 304-487-7000

Rowena Gonzales-Chambers
Principal Investigator

Wisconsin
Appleton

Fox Valley Hematology and Oncology

Timothy F. Goggins
Ph: 920-749-1171

Timothy F. Goggins
Principal Investigator

Burlington

Aurora Cancer Care-Burlington

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Eau Claire

Marshfield Clinic Cancer Center at Sacred Heart

Bilal H. Naqvi
Ph: 800-839-3956

Bilal H. Naqvi
Principal Investigator

Elkhorn

Aurora Cancer Care-Southern Lakes

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Grafton

Aurora Cancer Care-Grafton

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Green Bay

Aurora BayCare Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Green Bay Oncology at Saint Vincent Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Green Bay Oncology Limited at Saint Mary's Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Saint Mary's Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Saint Vincent Hospital

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Janesville

Mercy Health System

Emily Gray Robinson
Ph: 800-928-1103

Emily Gray Robinson
Principal Investigator

Kenosha

Aurora Cancer Care-Kenosha South

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

La Crosse

Gundersen Lutheran Medical Center

Kurt Oettel
Ph: 608-775-2385
Email: cancerctr@gundluth.org

Kurt Oettel
Principal Investigator

Madison

Dean Hematology and Oncology Clinic

Amit Sanyal
Ph: 608-410-2700

Amit Sanyal
Principal Investigator

Marinette

Bay Area Medical Center

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Vince Lombardi Cancer Clinic-Marinette

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Marshfield

Marshfield Clinic

Bilal H. Naqvi
Ph: 800-839-3956

Bilal H. Naqvi
Principal Investigator

Saint Joseph's Hospital

Bilal H. Naqvi
Ph: 800-839-3956

Bilal H. Naqvi
Principal Investigator

Menomonee Falls

Aurora Advanced Healthcare Inc-Menomonee Falls

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Milwaukee

Aurora Cancer Care-Milwaukee

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Saint Luke's Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Sinai Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Froedtert and the Medical College of Wisconsin

Ehab Latif Atallah
Ph: 414-805-4380

Ehab Latif Atallah
Principal Investigator

Minocqua

Marshfield Clinic-Minocqua Center

Bilal H. Naqvi
Ph: 800-839-3956

Bilal H. Naqvi
Principal Investigator

Oconomowoc

Oconomowoc Memorial Hospital-ProHealth Care Inc

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

Oconto Falls

Green Bay Oncology - Oconto Falls

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Oshkosh

Vince Lombardi Cancer Clinic - Oshkosh

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Racine

Aurora Cancer Care-Racine

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Rhinelander

Marshfield Clinic at James Beck Cancer Center

Bilal H. Naqvi
Ph: 800-839-3956

Bilal H. Naqvi
Principal Investigator

Rice Lake

Marshfield Clinic-Rice Lake Center

Bilal H. Naqvi
Ph: 800-839-3956

Bilal H. Naqvi
Principal Investigator

Sheboygan

Vince Lombardi Cancer Clinic-Sheboygan

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Stevens Point

Marshfield Clinic Cancer Care at Saint Michael's Hospital

Bilal H. Naqvi
Ph: 800-839-3956

Bilal H. Naqvi
Principal Investigator

Sturgeon Bay

Green Bay Oncology - Sturgeon Bay

Brian Leslie Burnette
Ph: 800-432-6049

Brian Leslie Burnette
Principal Investigator

Summit

Aurora Medical Center in Summit

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Two Rivers

Vince Lombardi Cancer Clinic

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Waukesha

Aurora Cancer Care-Waukesha

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Waukesha Memorial Hospital

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

Wausau

Aspirus Regional Cancer Center

Hamied R. Rezazadeh
Ph: 877-405-6866

Hamied R. Rezazadeh
Principal Investigator

Wauwatosa

Aurora Cancer Care-Milwaukee West

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

West Allis

Aurora West Allis Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Weston

Marshfield Clinic - Weston Center

Bilal H. Naqvi
Ph: 800-839-3956

Bilal H. Naqvi
Principal Investigator

Wisconsin Rapids

Marshfield Clinic - Wisconsin Rapids Center

Bilal H. Naqvi
Ph: 800-839-3956

Bilal H. Naqvi
Principal Investigator

Riverview Hospital

Ronnie James Kirschling
Ph: 877-405-6866

Ronnie James Kirschling
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00843882

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.